Pulmonary fibrosis in the aftermath of the Covid-19 era (Review)
- Eirini Vasarmidi
- Eliza Tsitoura
- Demetrios A. Spandidos
- Nikolaos Tzanakis
- Katerina M. Antoniou
Affiliations: Department of Respiratory Medicine, University General Hospital of Heraklion, Laboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, 71003 Heraklion, Greece, Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece
- Published online on: July 9, 2020 https://doi.org/10.3892/etm.2020.8980
Copyright: © Vasarmidi
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The year 2020 is characterized by the COVID‑19 pandemic that has resulted in more than half a million deaths in recent months. The high mortality is associated with acute severe respiratory failure that results in ICU admission and intubation. While facing this fatal disease, research and clinical observations need to be carried out in order to evaluate the long‑term effects of the COVID‑19 acute respiratory distress syndrome (ARDS). Potent clinical and laboratory biomarkers should be studied to be able to predict the subgroup of patients that are going to deteriorate or develop lung fibrosis. The opportunity of personalized medicine is a good way to consider for these patients.